ALKS - Alkermes PLC Stock Price, Fair Value and News

23.89USD+0.04 (+0.17%)Delayed as of 22 Apr 2024, 12:03 pm ET

Market Summary

USD23.89+0.04

Delayedas of 22 Apr 2024, 12:03 pm

0.17%

ALKS Alerts

1 major insider sales recently.

ALKS Stock Price

View Fullscreen

ALKS RSI Chart

ALKS Valuation

Market Cap

4.0B

Price/Earnings (Trailing)

11.2

Price/Sales (Trailing)

2.4

EV/EBITDA

7.34

Price/Free Cashflow

11.28

ALKS Price/Sales (Trailing)

ALKS Profitability

EBT Margin

25.34%

Return on Equity

29.58%

Return on Assets

16.65%

Free Cashflow Yield

8.87%

ALKS Fundamentals

ALKS Revenue

Revenue (TTM)

1.7B

Rev. Growth (Yr)

23.89%

Rev. Growth (Qtr)

-0.91%

ALKS Earnings

Earnings (TTM)

355.8M

Earnings Growth (Yr)

499.16%

Earnings Growth (Qtr)

136.15%

Breaking Down ALKS Revenue

52 Week Range

23.7733.71

(Low)(High)

Last 7 days

-2.3%

Last 30 days

-13.9%

Last 90 days

-14.5%

Trailing 12 Months

-17.8%

How does ALKS drawdown profile look like?

ALKS Financial Health

Current Ratio

2.86

Debt/Equity

0.24

Debt/Cashflow

1.39

ALKS Investor Care

Shares Dilution (1Y)

1.63%

Diluted EPS (TTM)

2.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.1B	1.5B	1.6B	1.7B
2022	1.2B	1.2B	1.1B	1.1B
2021	1.0B	1.1B	1.1B	1.2B
2020	1.2B	1.2B	1.2B	1.0B
2019	1.1B	1.1B	1.1B	1.2B
2018	936.7M	1.0B	1.1B	1.1B
2017	780.7M	804.4M	841.5M	903.4M
2016	623.9M	667.7M	695.3M	745.7M
2015	649.8M	647.7M	640.4M	628.3M
2014	563.1M	577.9M	598.1M	618.8M
2013	575.5M	561.9M	577.8M	596.3M
2012	390.0M	480.3M	532.3M	542.6M
2011	186.6M	219.3M	242.1M	331.8M
2010	178.3M	0	181.1M	183.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Alkermes PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	nichols christian todd	sold	-292,740	28.1021	-10,417	svp, chief commercial officer
Feb 27, 2024	parisi samuel joseph	sold	-75,874	29.65	-2,559	vp, finance (interim pao)
Feb 23, 2024	brown iain michael	acquired	-	-	5,825	svp, chief financial officer
Feb 23, 2024	parisi samuel joseph	acquired	-	-	2,283	vp, finance (interim pao)
Feb 23, 2024	gaffin david joseph	acquired	-	-	7,689	evp, clo, alkermes, inc.
Feb 23, 2024	jackson blair curtis	sold (taxes)	-114,732	29.57	-3,880	evp, chief operating officer
Feb 23, 2024	landine michael j	acquired	-	-	4,077	svp, corp dev., alkermes, inc.
Feb 23, 2024	nichols christian todd	sold (taxes)	-84,126	29.57	-2,845	svp, chief commercial officer
Feb 23, 2024	jackson blair curtis	acquired	-	-	8,737	evp, chief operating officer
Feb 23, 2024	brown iain michael	sold (taxes)	-76,497	29.57	-2,587	svp, chief financial officer

Which funds bought or sold ALKS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-68.03	-7,204,170	3,267,380	-%
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-100	-29,765	-	-%
Apr 18, 2024	AlphaMark Advisors, LLC	new	-	297,000	297,000	0.10%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	-	-%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	-67.00	2,707	-%
Apr 18, 2024	Diversified Trust Co	reduced	-10.41	-131,117	911,934	0.03%
Apr 18, 2024	Measured Wealth Private Client Group, LLC	added	28.51	53,099	262,092	0.09%
Apr 18, 2024	SJS Investment Consulting Inc.	unchanged	-	-1.00	55.00	-%
Apr 18, 2024	Hexagon Capital Partners LLC	reduced	-79.14	-4,132	1,056	-%
Apr 17, 2024	GUIDANCE CAPITAL, INC	new	-	380,141	380,141	0.14%

Are Funds Buying or Selling ALKS?

Are funds buying ALKS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALKS

No. of Funds

ALKS Alerts

1 major insider sales recently.

Unveiling Alkermes PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	12.56%	20,955,454	SC 13G/A
Feb 08, 2024	wellington management group llp	9.13%	15,241,470	SC 13G
Jan 24, 2024	state street corp	5.60%	9,352,970	SC 13G
Jan 08, 2024	blackrock inc.	18.0%	30,021,312	SC 13G/A
Aug 24, 2023	sarissa capital management lp	997%	8,323,400	SC 13D/A
Jun 28, 2023	sarissa capital management lp	-	0	SC 13D/A
Jun 27, 2023	sarissa capital management lp	-	0	SC 13D/A
Jun 23, 2023	sarissa capital management lp	-	0	SC 13D/A
Jun 21, 2023	sarissa capital management lp	-	0	SC 13D/A
Jun 16, 2023	sarissa capital management lp	-	0	SC 13D/A

Recent SEC filings of Alkermes PLC

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	DEFA14A	DEFA14A
Apr 12, 2024	4	Insider Trading
Apr 09, 2024	8-K	Current Report
Apr 05, 2024	PRE 14A	PRE 14A
Mar 18, 2024	144	Notice of Insider Sale Intent
Mar 18, 2024	4	Insider Trading
Mar 15, 2024	3	Insider Trading
Mar 07, 2024	8-K	Current Report

Peers (Alternatives to Alkermes PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	356.3B	85.2B	-5.03%	-9.57%	10.14	4.18	6.46%	95.94%
MRK	318.7B	60.1B	1.61%	10.23%	873.24	5.3	1.40%	-97.49%
PFE	146.8B	46.5B	-6.17%	-34.78%	-105.7	3.15	42.59%	-114.62%
AMGN	144.1B	28.2B	-1.51%	10.46%	21.46	5.11	7.09%	2.52%
GILD	83.2B	27.1B	-9.77%	-21.18%	14.68	3.07	-0.60%	23.36%
TEVA	14.4B	15.8B	-4.60%	54.01%	-25	0.91	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	-1.63%	-14.16%	-328.65	0.9	4.58%	90.97%
ALKS	4.0B	1.7B	-13.93%	-17.76%	11.2	2.4	49.61%	324.78%
BHC	3.2B	8.8B	-9.38%	13.00%	-5.36	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-9.13%	-7.04%	13.99	2.99	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-12.63%	-26.38%	-3.8	1.8	24.65%	80.36%
TXMD	21.6M	1.3M	-20.43%	-49.32%	-2.1	16.56	-98.14%	-109.18%
ACRX	16.6M	-	-10.09%	36.11%	-0.9	0.22	2882.68%	-138.52%
AGRX	2.6M	19.6M	-34.48%	-94.22%	-0.18	0.13	80.00%	43.08%
ACOR	546.5K	117.6M	-96.48%	-95.45%	0	0	-0.79%	-283.60%

Alkermes PLC News

Latest updates

Alkermes PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-0.9%	377,475	380,938	617,397	287,595	304,674	252,357	276,219	278,545	324,463	294,141	303,717	251,430	279,995	265,012	247,529	246,220	412,730	255,243	279,872	223,102	315,762
Costs and Expenses	-41.0%	198,900	337,090	378,204	335,089	189,080	312,998	310,676	305,130	195,047	313,800	299,296	267,862	310,724	275,679	281,190	283,590	422,664	308,864	315,795	299,103	315,742
S&GA Expenses	-17.0%	140,570	169,446	205,258	174,477	142,545	152,777	150,377	145,052	149,041	136,213	139,188	125,168	145,778	127,653	132,025	133,372	154,453	148,701	155,075	141,220	141,227
R&D Expenses	-121.4%	-20,759	97,140	100,788	93,637	-16,554	100,430	92,873	95,953	-17,228	118,411	97,473	92,268	112,107	94,980	94,222	93,279	198,157	107,671	104,435	102,570	108,972
EBITDA Margin	10.0%	0.31*	0.28*	0.14*	-0.07*	-0.07*	-0.05*	-0.01*	0.02*	0.04*	0.01*	0.03*	0.01*	-	-	-	-	-	-	-	-	-
Interest Expenses	0.8%	6,054	6,006	5,684	5,288	4,769	3,552	2,369	2,350	2,405	2,437	2,407	3,970	1,869	1,811	2,122	2,857	3,196	3,385	3,520	3,500	3,478
Income Taxes	-23559.6%	-93,928	-397	2,688	-6,010	17,627	-3,394	-3,114	-9,095	1,817	2,453	3,291	3,765	996	2,326	3,673	7,329	2,797	-983	1,604	-3,854	8,022
Earnings Before Taxes	284.8%	182,260	47,361	239,753	-47,855	114,488	-67,368	-33,250	-44,998	127,260	-26,535	5,655	-18,653	-41,646	2,192	-25,758	-31,325	-2,557	-53,861	-40,386	-100,252	-1,691
EBT Margin	13.9%	0.25*	0.22*	0.07*	-0.15*	-0.15*	-0.13*	-0.09*	-0.05*	-0.03*	-0.07*	-0.05*	-0.08*	-	-	-	-	-	-	-	-	-
Net Income	136.1%	112,779	47,758	237,065	-41,845	-28,254	-63,974	-30,136	-35,903	873	-28,988	2,364	-22,418	-42,642	-134	-29,431	-38,654	-5,354	-52,878	-41,990	-96,398	-9,713
Net Income Margin	58.4%	0.21*	0.13*	0.07*	-0.15*	-0.14*	-0.11*	-0.08*	-0.05*	-0.04*	-0.08*	-0.06*	-0.09*	-	-	-	-	-	-	-	-	-
Free Cashflow	5.8%	90,207	85,255	206,005	-28,162	-8,981	-9,849	-12,268	13,887	22,360	77,964	26,503	-53,132	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-6.3%	2,136	2,279	2,187	1,923	1,964	1,942	1,957	1,978	2,024	1,995	1,938	1,878	1,950	1,877	1,802	1,826	1,805	1,758	1,752	1,757	1,825
Current Assets	1.4%	1,486	1,465	1,397	1,110	1,130	1,054	1,046	1,015	1,062	1,053	1,038	1,006	1,111	1,025	947	913	962	998	995	963	983
Cash Equivalents	-29.4%	457	648	666	321	292	264	255	283	338	310	258	205	273	241	189	176	204	261	196	225	267
Inventory	-3.0%	186	192	189	185	181	166	156	155	150	139	136	134	126	123	116	109	102	101	95.00	93.00	90.00
Net PPE	-30.7%	227	328	324	321	223	326	337	337	341	341	344	346	350	355	362	363	362	341	326	320	310
Goodwill	-10.6%	83.00	93.00	93.00	93.00	83.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00	93.00
Liabilities	1.1%	934	924	907	917	920	899	875	902	912	899	840	827	883	792	740	763	720	690	661	654	654
Current Liabilities	3.4%	520	503	487	493	498	470	439	462	471	453	383	366	438	378	321	340	391	370	334	328	340
Long Term Debt	-0.2%	288	288	289	290	290	291	292	292	293	293	294	295	272	273	273	274	274	275	275	276	276
LT Debt, Current	0%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
LT Debt, Non Current	-0.2%	288	288	289	290	290	291	292	292	293	293	294	295	272	273	273	274	274	275	275	276	276
Shareholder's Equity	-11.3%	1,203	1,356	1,280	1,006	1,044	1,043	1,082	1,075	1,113	1,096	1,098	1,051	1,067	1,084	1,062	1,063	1,085	1,068	1,091	1,102	1,171
Retained Earnings	7.7%	-1,343	-1,456	-1,504	-1,741	-1,699	-1,671	-1,607	-1,576	-1,541	-1,541	-1,512	-1,515	-1,492	-1,450	-1,450	-1,420	-1,381	-1,376	-1,323	-1,281	-1,185
Additional Paid-In Capital	-8.9%	2,737	3,003	2,976	2,939	2,913	2,886	2,858	2,819	2,798	2,779	2,749	2,703	2,686	2,660	2,636	2,609	2,586	2,563	2,533	2,503	2,467
Shares Outstanding	0.2%	167	167	166	166	164	164	164	162	161	161	160	160	-	-	-	-	-	-	-	-	-
Float	-	-	-	4,792	-	-	-	4,838	-	-	-	3,918	-	-	-	3,058	-	-	-	3,508	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	7.6%	107,237	99,708	215,710	-21,302	1,047	625	-2,306	21,678	31,021	82,777	33,063	-45,146	67,343	60,203	-4,432	-40,272	42,070	30,972	-23,177	22,212	60,513
Share Based Compensation	8.1%	25,843	23,915	28,504	22,643	26,483	26,051	23,377	18,343	19,019	25,600	27,552	15,451	24,885	22,620	22,846	19,813	21,387	26,729	28,245	24,616	29,314
Cashflow From Investing	82.4%	-20,982	-119,359	120,848	72,850	27,740	8,898	-40,538	-60,641	-742	-31,707	3,977	-37,732	-35,097	-8,227	14,351	17,492	-101,471	31,594	-7,253	-64,703	-7,803
Cashflow From Financing	-17745.0%	-276,497	1,567	7,836	-22,620	-271	-212	14,933	-16,024	-3,179	1,033	16,273	14,945	-151	-112	3,016	-4,924	1,746	2,906	1,150	963	-1,989

ALKS Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
REVENUES:
Total revenues	$ 1,663,405	$ 1,111,795	$ 1,173,751
EXPENSES:
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)	253,037	218,068	197,323
Research and development	270,806	272,702	290,924
Selling, general and administrative	689,751	590,751	549,610
Amortization of acquired intangible assets	35,689	36,363	38,148
Total expenses	1,249,283	1,117,884	1,076,005
OPERATING INCOME (LOSS)	414,122	(6,089)	97,746
OTHER INCOME (EXPENSE), NET:
Interest income	30,854	7,629	2,408
Interest expense	(23,032)	(13,040)	(11,219)
Change in the fair value of contingent consideration		(21,750)	(1,427)
Other (expense) income, net	(425)	2,122	219
Total other income (expense), net	7,397	(25,039)	(10,019)
INCOME (LOSS) BEFORE INCOME TAXES	421,519	(31,128)	87,727
INCOME TAX (BENEFIT) PROVISION	(97,638)	2,024	11,326
NET INCOME (LOSS) FROM CONTINUING OPERATIONS	519,157	(33,152)	76,401
DISCONTINUED OPERATIONS, NET OF TAX	(163,400)	(125,115)	(124,570)
NET INCOME (LOSS)	$ 355,757	$ (158,267)	$ (48,169)
EARNINGS (LOSS) PER ORDINARY SHARE:
Earnings (loss) per share from continuing operations - basic	$ 3.12	$ (0.2)	$ 0.47
Earnings (loss) per share from discontinued operations - basic	(0.98)	(0.76)	(0.77)
Earnings (loss) per share - basic	2.14	(0.97)	(0.3)
Earnings (loss) per share from continuing operations - diluted	3.06	(0.2)	0.46
Earnings (loss) per share from discontinued operations - diluted	(0.96)	(0.76)	(0.76)
Earnings (loss) per share - diluted	$ 2.1	$ (0.97)	$ (0.29)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:
Basic	166,223	163,742	160,942
Diluted	169,730	163,742	164,753
COMPREHENSIVE INCOME (LOSS):
Net Income (Loss)	$ 355,757	$ (158,267)	$ (48,169)
Holding gain (loss), net of a tax provision (benefit) of $1,195, $(973) and $(706), respectively	7,779	(7,166)	(2,374)
COMPREHENSIVE INCOME (LOSS)	363,536	(165,433)	(50,543)
Product sales, net
REVENUES:
Total revenues	919,998	777,552	627,424
Manufacturing and royalty revenues
REVENUES:
Total revenues	743,388	331,983	541,807
License revenue
REVENUES:
Total revenues		2,000	3,500
Research and development revenue
REVENUES:
Total revenues	$ 19	$ 260	$ 1,020

ALKS Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 457,469	$ 292,473
Receivables, net	332,477	287,967
Investments—short-term	316,022	315,992
Inventory	186,406	181,418
Contract assets	706	8,929
Prepaid expenses and other current assets	98,166	41,203
Assets related to discontinued operations		2,324
Assets held for sale	94,260
Total current assets	1,485,506	1,130,306
PROPERTY, PLANT AND EQUIPMENT, NET	226,943	222,919
INVESTMENTS—LONG-TERM	39,887	131,610
RIGHT-OF-USE ASSETS	91,460	97,539
ASSETS RELATED TO DISCONTINUED OPERATIONS-LONG-TERM		37,763
ASSETS HELD FOR SALE-LONG-TERM		93,871
INTANGIBLE ASSETS, NET	1,991	37,680
GOODWILL	83,027	83,027
DEFERRED TAX ASSETS	195,888	114,572
OTHER ASSETS	11,521	14,691
TOTAL ASSETS	2,136,223	1,963,978
CURRENT LIABILITIES:
Accounts payable and accrued expenses	240,561	220,089
Accrued sales discounts, allowances and reserves	263,641	252,115
Operating lease liabilities—short-term	5,746	9,878
Contract liabilities—short-term	2,730	6,816
Current portion of long-term debt	3,000	3,000
Liabilities related to discontinued operations	4,542	5,844
Total current liabilities	520,220	497,742
LONG-TERM DEBT	287,730	290,270
OPERATING LEASE LIABILITIES—LONG-TERM	75,709	76,287
LIABILITIES RELATED TO DISCONTINUED OPERATIONS-LONG-TERM		13,542
OTHER LONG-TERM LIABILITIES	49,878	42,384
Total liabilities	933,537	920,225
COMMITMENTS AND CONTINGENT LIABILITIES (Note 19)
SHAREHOLDERS’ EQUITY:
Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at December 31, 2023 and 2022, respectively
Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 172,569,051 and 168,951,193 shares issued; 166,979,833 and 164,377,009 shares outstanding at December 31, 2023 and 2022, respectively	1,726	1,690
Treasury shares, at cost (5,589,218 and 4,574,184 shares at December 31, 2023 and 2022, respectively)	(189,336)	(160,862)
Additional paid-in capital	2,736,934	2,913,099
Accumulated other comprehensive loss	(3,110)	(10,889)
Accumulated deficit	(1,343,528)	(1,699,285)
Total shareholders’ equity	1,202,686	1,043,753
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 2,136,223	$ 1,963,978

About Alkermes PLC

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

CEO	Mr. Richard F. Pops
WEBSITE	alkermes.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	2280

Alkermes PLC Frequently Asked Questions

What is the ticker symbol for Alkermes PLC? What does ALKS stand for in stocks?

ALKS is the stock ticker symbol of Alkermes PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alkermes PLC (ALKS)?

As of Fri Apr 19 2024, market cap of Alkermes PLC is 3.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALKS stock?

You can check ALKS's fair value in chart for subscribers.

What is the fair value of ALKS stock?

You can check ALKS's fair value in chart for subscribers. The fair value of Alkermes PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alkermes PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALKS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alkermes PLC a good stock to buy?

The fair value guage provides a quick view whether ALKS is over valued or under valued. Whether Alkermes PLC is cheap or expensive depends on the assumptions which impact Alkermes PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALKS.

What is Alkermes PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, ALKS's PE ratio (Price to Earnings) is 11.2 and Price to Sales (PS) ratio is 2.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALKS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alkermes PLC's stock?

In the past 10 years, Alkermes PLC has provided -0.066 (multiply by 100 for percentage) rate of return.